NCT06526000已完成不适用
Retrospective EMR Study to Assess Changes in Immunoglobulins in Patients With Relapsing Forms of Multiple Sclerosis Treated With Anti-CD20 Monoclonal Antibodies
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Novartis
- 入组人数
- 326
- 试验地点
- 1
- 主要终点
- Percentage Change per Year in Immunoglobulin G (IgG) Levels in Patients Receiving Ocrelizumab
研究概览
简要总结
This was an observational retrospective cohort study using electronic medical records (EMRs) to study immunoglobulin levels over time among patients with relapsing forms of multiple sclerosis (MS) newly initiating anti-CD20 monoclonal antibody treatment in clinical practice.
The index date was defined as the date of anti-CD20 drug initiation during the study period. The baseline period was defined as 12 months prior to the index date.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Percentage Change per Year in Immunoglobulin G (IgG) Levels in Patients Receiving Ocrelizumab
时间窗: Up to 5 years
次要结局
- Percentage of Patients Newly Treated with Ocrelizumab With Low Immunoglobulin Values(Up to 5 years)
- Percentage Change per Year in Immunoglobulin M (IgM) Levels in Patients Receiving Ocrelizumab(Up to 5 years)
- Percentage Change per Year in IgG Levels Associated With Risk Factors in Patients Treated With Ocrelizumab(Up to 5 years)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Adalimumab Biosimilar in Clinical PracticePsoriasisNCT04808739Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau604
已完成
不适用
A Study to go Back Into Records and Observe How People With Metastatic Renal Cell Carcinoma (mRCC) Who Received a Medicine Called Sunitinib Responded to This Medicine.Carcinoma, Renal CellClear-cell Metastatic Renal Cell CarcinomaNCT05745142Pfizer376
已完成
不适用
Real World Effectiveness, Persistence, Tolerability, and Safety of Ofatumumab in Clinical PracticeMultiple SclerosisNCT06737419Novartis Pharmaceuticals175
已完成
不适用
Nivolumab in the Real World: Analysis of the Expanded Use in Spanish PatientNon Small Cell Lung CancerNCT03132493Spanish Lung Cancer Group676
已完成
不适用
eVusheld Assessment reaL wORld Effectiveness at UPMCSARS-CoV-2, COVID-19NCT05667116AstraZeneca4,232